Biosimilars in the EU are essentially branded generics, i.e. they are non-substitutable for the original brand and they have to be actively marketed.
HSP’s Neupogen knockoff will be sold under the brand name, Nivestim. It will have to compete with several other Neupogen biosimilars as well as AMGN’s original product, so it probably won’t be a big moneymaker.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.